Insmed reported $-153275000 in EBIT for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebit Change
DBV Technologies DBVT:US USD -38017000 20M
Acelrx Pharmaceuticals ACRX:US USD -6632000 2.04M
Alimera Sciences ALIM:US USD -3411000 1.44M
Biomarin Pharmaceutical BMRN:US USD -24500000 22.08M
Cytokinetics CYTK:US USD -127030000 18.59M
Dynavax Technologies DVAX:US USD 63.77M 1.93M
Gilead Sciences GILD:US USD 2.27B 565M
Heron Therapeutics HRTX:US USD -41882000 7.62M
Insmed INSM:US USD -153275000 30.82M
Mirati Therapeutics MRTX:US USD -211723000 25.28M
Novartis NVS:US USD 3.1B 228M
Regeneron Pharmaceuticals REGN:US USD 1.18B 46.9M
Sarepta Therapeutics SRPT:US USD -106833000 24.52M
Seattle Genetics SGEN:US USD -154004000 38.8M
Ultragenyx Pharmaceutical RARE:US USD -145628000 79.44M
Vertex Pharmaceuticals VRTX:US USD 1.04B 89.7M